NCT01505387

Brief Summary

The effect of Litramine on weight loss has previously been studied during a 12-week intervention period with promising results. The present study looks into the effect of weight maintenance using Litramine following initial weight loss, for a longer period of 24 weeks.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Jan 2012

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2012

Completed
3 days until next milestone

First Submitted

Initial submission to the registry

January 4, 2012

Completed
2 days until next milestone

First Posted

Study publicly available on registry

January 6, 2012

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2012

Completed
2.6 years until next milestone

Results Posted

Study results publicly available

April 3, 2015

Completed
Last Updated

June 1, 2015

Status Verified

May 1, 2015

Enrollment Period

8 months

First QC Date

January 4, 2012

Results QC Date

March 24, 2015

Last Update Submit

May 13, 2015

Conditions

Keywords

Weight maintenanceOverweightObeseWeight management

Outcome Measures

Primary Outcomes (1)

  • Mean Change in Body Weight From Baseline to End of 24 Weeks

    Change in body weight at the end of 24 weeks measured in kg using a calibrated scale. (positive values signify weight gain, while negative values signify weight reduction

    24 weeks

Secondary Outcomes (4)

  • Waist and Hip Circumference (cm)

    24 weeks

  • Body Mass Index (kg/m^2)

    24 weeks

  • Full Blood Count

    24 weeks

  • Blood Pressure

    24 weeks

Study Arms (2)

Placebo

PLACEBO COMPARATOR

Identical to Litramine 2 tablets 3 times daily (oral consumption, after meal)

Dietary Supplement: Placebo

Litramine

EXPERIMENTAL

Fibre complex of plant origin n tablet form 2 tablets 3 times daily (oral consumption, after meal)

Dietary Supplement: Litramine

Interventions

LitramineDIETARY_SUPPLEMENT

Fibre complex of plant origin in tablet form 2 tablets 3 times daily (oral consumption, after meal)

Litramine
PlaceboDIETARY_SUPPLEMENT

Identical to Litramine tablets 2 tablets 3 times daily (oral consumption, after meal)

Placebo

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Documented weight loss, achieved over the last 3 to 6 months either from participation in weight loss clinical trials or weight loss regimens, of at least 3% at the point of screening
  • BMI 25-35 before initial weight loss
  • Documented compliance (according to the investigator's judgement) to previous weight loss clinical trials/ regimens

You may not qualify if:

  • Known sensitivity to the ingredients of the device (citric acid, acacia or Fabaceae family)
  • BMI \< 18.5
  • Presence of other factor(s) that, in the investigator's judgement, should preclude subject participation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Barbara Grube

Berlin, State of Berlin, 10709, Germany

Location

Related Publications (1)

  • Grube B, Chong PW, Alt F, Uebelhack R. Weight Maintenance with Litramine (IQP-G-002AS): A 24-Week Double-Blind, Randomized, Placebo-Controlled Study. J Obes. 2015;2015:953138. doi: 10.1155/2015/953138. Epub 2015 Sep 7.

MeSH Terms

Conditions

OverweightObesity

Condition Hierarchy (Ancestors)

OvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Results Point of Contact

Title
Felix Alt
Organization
Analyze & Realize

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 4, 2012

First Posted

January 6, 2012

Study Start

January 1, 2012

Primary Completion

September 1, 2012

Study Completion

September 1, 2012

Last Updated

June 1, 2015

Results First Posted

April 3, 2015

Record last verified: 2015-05

Locations